@Article{or.2022.028449,
AUTHOR = {YI-NONG CHEN, YING-LIN CHEN, WAN-MING CHEN, MINGCHIH CHEN, BEN-CHANG SHIA, JENQ-YUH KO, SZU-YUAN WU},
TITLE = {H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus},
JOURNAL = {Oncology Research},
VOLUME = {31},
YEAR = {2023},
NUMBER = {1},
PAGES = {23--34},
URL = {http://www.techscience.com/or/v31n1/51752},
ISSN = {1555-3906},
ABSTRACT = {This study aimed to examine the association between the use of H1-antihistamines (AHs) and head and neck
cancer (HNC) risk in patients with type 2 diabetes mellitus (T2DM). Data from the National Health Insurance Research
Database of Taiwan were analyzed for the period from 2008 to 2018. A propensity-score-matched cohort of 54,384
patients each in the AH user and nonuser groups was created and analyzed using Kaplan-Meier method and Cox
proportional hazards regression. The results showed that the risk of HNC was significantly lower in AH users
(adjusted hazard ratio: 0.55, 95% CI: 0.48 to 0.64) and the incidence rate was also lower (5.16 vs. 8.10 per 100,000
person-years). The lower HNC incidence rate in AH users (95% CI: 0.63; 0.55 to 0.73) suggests that AH use may
reduce the risk of HNC in T2DM patients.},
DOI = {10.32604/or.2022.028449}
}